CXCL12 is a potential therapeutic target for type 2 diabetes mellitus complicated by chronic obstructive pulmonary disease.
10.12122/j.issn.1673-4254.2025.01.13
- Author:
Huaiwen XU
1
;
Li WENG
2
;
Hong XUE
2
Author Information
1. Department of Clinical Medicine, Fujian Medical University, Fuzhou 350122, China.
2. Provincial School of Clinical Medicine, Fujian Medical University; Department of Respiratory and Critical Care Medicine, Fujian Provincial Hospital of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou 350001, China.
- Publication Type:Journal Article
- Keywords:
CXCL12;
bioinformatics analysis;
chronic obstructive pulmonary disease;
drug target analysis;
type 2 diabetes mellitus
- MeSH:
Humans;
Pulmonary Disease, Chronic Obstructive/complications*;
Diabetes Mellitus, Type 2/genetics*;
Chemokine CXCL12/metabolism*;
Protein Interaction Maps;
Gene Expression Profiling
- From:
Journal of Southern Medical University
2025;45(1):100-109
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:To identify the key genes and immunological pathways shared by type 2 diabetes mellitus (T2DM) and chronic obstructive pulmonary disease (COPD) and explore the potential therapeutic targets of T2DM complicated by COPD.
METHODS:GEO database was used for analyzing the gene expression profiles in T2DM and COPD to identify the common differentially expressed genes (DEGs) in the two diseases. A protein-protein interaction network was constructed to identify the candidate hub genes, which were validated in datasets and disease sets to obtain the target genes. The diagnostic accuracy of these target genes was assessed with ROC analysis, and their expression levels and association with pulmonary functions were investigated using clinical data and blood samples of patients with T2DM and COPD. The abundance of 22 immune cells was analyzed with CIBERSORT algorithm, and their relationship with the target genes was examined using correlation analysis. DGIdb database was used for analyzing the drug-gene interactions and the druggable genes followed by gene set enrichment analysis.
RESULTS:We identified a total of 175 common DEGs in T2DM and COPD, mainly enriched in immune- and inflammation-related pathways. Among these genes, CXCL12 was identified as the final target gene, whose expression was elevated in both T2DM and COPD (P<0.05) and showed good diagnostic efficacy. Immune cell infiltration correlation analysis showed significant correlations of CXCL12 with various immune cells (P<0.01). GESA analysis showed that high CXCL12 expression was significantly correlated with "cytokine-cytokine receptor interaction". Drug-gene analysis showed that most of CXCL12-related drugs were not targeted drugs with significant cytotoxicity.
CONCLUSIONS:CXCL12 is a potential common key pathogenic gene of COPD and T2DM, and small-molecule targeted drugs against CXCL12 can provide a new strategy for treatment T2DM complicated by COPD.
